Zimmermann H, Zebisch M, Sträter N (2012) Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 8:437–502

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53(4):527–52

CAS  PubMed  Google Scholar 

Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 63(1):1–34

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Rashida M, Qazi SU, Batool N, Hameed A, Iqbal J (2017) Ectonucleotidase inhibitors: a potent review (2011–2016). Expert Opin Ther Pat 27(12):1291–1304

Article  CAS  PubMed  Google Scholar 

Gao Z-G, Jacobson KA (2007) Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 12(3):479–492

Article  CAS  PubMed  Google Scholar 

Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA et al (1997) Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 18(3):79

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tozaki-Saitoh H, Takeda H, Inoue K (2022) The role of microglial purinergic receptors in pain signaling. Molecules 27(6):1919

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haskó G, Pacher P (2008) A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 83(3):447–455

Article  PubMed  Google Scholar 

Nishat S, Khan LA, Ansari ZM, Basir SF (2016) Adenosine A3 receptor: a promising therapeutic target in cardiovascular disease. Curr Cardiol Rev 12(1):18–26

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahmood A, Iqbal J (2022) Purinergic receptors modulators: an emerging pharmacological tool for disease management. Med Res Rev 42(4):1661–1703

Article  CAS  PubMed  Google Scholar 

Bao X, Xie L (2022) Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. J Exp Clin Cancer Res 41(1):1–18

Article  Google Scholar 

Jacob F, Novo CP, Bachert C, Van Crombruggen K (2013) Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal 9:285–306

Article  CAS  PubMed  PubMed Central  Google Scholar 

North RA (2016) P2X receptors. Philos Trans R Soc B: Biol Sci 371(1700):20150427

Article  Google Scholar 

Baqi Y (2015) Ecto-nucleotidase inhibitors: recent developments in drug discovery. Mini Rev Med Chem 15(1):21–33

Article  CAS  PubMed  Google Scholar 

Hechler B, Cattaneo M, Gachet C, editors. The P2 receptors in platelet function. Seminars in thrombosis and hemostasis; 2005: Copyright 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York.

Burnstock G (2012) Purinergic signalling: its unpopular beginning, its acceptance and its exciting future. BioEssays 34(3):218–225

Article  CAS  PubMed  Google Scholar 

Lazarowski ER (2012) Vesicular and conductive mechanisms of nucleotide release. Purinergic Signal 8(3):359–373

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burnstock G (2017) Purinergic signalling and neurological diseases: an update. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 16(3):257–65

CAS  Google Scholar 

von Kügelgen I, Hoffmann K (2016) Pharmacology and structure of P2Y receptors. Neuropharmacology 104:50–61

Article  Google Scholar 

Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S et al (2013) Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61(8):872–879

Article  CAS  PubMed  Google Scholar 

Cattaneo M (2015) P2Y12 receptors: structure and function. J Thromb Haemost 13:S10–S16

Article  CAS  PubMed  Google Scholar 

Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H (2009) Purinergic signalling in the nervous system: an overview. Trends Neurosci 32(1):19–29

Article  CAS  PubMed  Google Scholar 

Haas CB, Lovászi M, Braganhol E, Pacher P, Haskó G (2021) Ectonucleotidases in inflammation, immunity, and cancer. J Immunol 206(9):1983–1990

Article  CAS  PubMed  Google Scholar 

Nitschke Y, Rutsch F (2012) Genetics in arterial calcification: lessons learned from rare diseases. Trends Cardiovasc Med 22(6):145–149

Article  CAS  PubMed  Google Scholar 

Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K et al (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158(2):227–233

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrero E, Faini AC, Malavasi F (2019) A phylogenetic view of the leukocyte ectonucleotidases. Immunol Lett 205:51–58

Article  CAS  PubMed  Google Scholar 

Johnson RC, Leopold JA, Loscalzo J (2006) Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 99(10):1044–1059

Article  CAS  PubMed  Google Scholar 

Choi J (2023) Small molecule ectonucleotide pyrophosphatase/phosphodiesterase 1 inhibitors in cancer immunotherapy for harnessing innate immunity. Bull Korean Chem Soc 44(2):88–99

Article  CAS  Google Scholar 

Antonioli L, Blandizzi C, Pacher P, Haskó G (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13(12):842–857

Article  CAS  PubMed  Google Scholar 

Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic signaling during inflammation. N Engl J Med 367(24):2322–2333

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allard B, Longhi MS, Robson SC, Stagg J (2017) The ectonucleotidases CD 39 and CD 73: novel checkpoint inhibitor targets. Immunol Rev 276(1):121–144

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ et al (2011) CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Investig 121(6):2371–2382

Article  CAS  PubMed  PubMed Central  Google Scholar